Hanmi Science Co., Ltd.

Hanmi Pharm. Co., Ltd.

Hanmi Holdings Co., Ltd.

Jin Sun Kim

Sung Youb Jung

Se Chang Kwon

Gwan Sun Lee

Geun Hee Yang

Young Jin Park

Dae Jin Kim

Ki-Doo Choi

Sung H Hong

Sang Hyun Lee

Gwan-Sun Lee

Dae Hae Song

Min Young Kim

Se-Chang Kwon

Jin Hwan Shin

Disclosed is an IgG Fc fragment useful as a drug carrier. A recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment are disclosed. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug.

IgG Fc fragment for a drug carrier and method for the preparation thereof

Disclosed are a composition for preventing or treating diabetes, disbesity or diabetic complications, containing an oxyntomodulin analog as an active ingredient and a method for treating diabetes, diabesity or diabetic complications, including administering a pharmaceutically effective amount of an oxyntomodulin analog to a subject. The oxyntomodulin analog shows a greater activity to activate a GLP-1 receptor and a glucagon receptor, than native oxyntomodulin. The oxyntomodulin analog induces an expansion of beta-cells and increases insulin secretion, thereby reducing blood glucose levels that were increased due to a high-calorie and high-fat diet. The oxyntomodulin analog induces decreases in a body weight and appetite to improve insulin sensitivity and is useful in maintaining normal blood glucose levels.

Composition for treating diabetes or diabesity comprising oxyntomodulin analog

The present invention relates to a long-acting interferon beta formulation having improved in vivo duration and stability, comprising an interferon beta conjugate that is prepared by covalently linking interferon beta with an immunoglobulin Fc region via a non-peptidyl polymer, and a preparation method thereof. The long-acting interferon beta formulation of the present invention maintains in vivo activity of interferon beta at a relatively high level and remarkably increases the serum half-life thereof, thereby being used for various diseases, for which interferon is efficacious.

Long-acting interferon beta formulation comprising an immunoglobulin fragment

Disclosed is an IgG Fc fragment useful as a drug carrier. Also, the present invention discloses a recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment, comprising culturing the transformant. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug.

Disclosed are a recombinant expression vector comprising a nucleotide sequence encoding an-derived signal sequence and a nucleotide sequence encoding an immunoglobulin constant region, and a transformant transformed with the expression vector. Also, disclosed is a method of mass-producing an immunoglobulin constant region by culturing the transformant and expressing the immunoglobulin constant region in a water-soluble form.

Method for the mass production of immunoglobulin constant region

Disclosed is a method for the mass production of a monomeric or dimeric immunoglobulin Fc region, free of initial methionine residues, using a recombinant expression vector comprising a nucleotide sequence coding for a recombinant immunoglobulin Fc region comprising an immunoglobulin Fc region linked at the N-terminus thereof to an immunoglobulin Fc region via a peptide bond.

Method for the mass production of immunoglobulin Fc region deleted initial methionine residues

A recombinant expression vector capable of expressing and secreting an antibody fragment fused withthermostable enterotoxin signal sequence derivative orouter membrane protein A (Omp A) signal sequence in the form of a soluble heterozygote protein is used to mass-produce the antibody fragment by culturing a microorganism transformed with the expression vector in a medium and collecting the antibody fragment secreted from the transformed microorganism into the medium.

Growing community of inventors

Kwangmyung-si, South Korea

Jin Sun Kim